# Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome

> **NCT07654114** · PHASE2 · RECRUITING · sponsor: **Connecta Therapeutics, S.L.** · enrollment: 30 (estimated)

## Conditions studied

- Fragile X Syndrome (FXS)
- Fragile X Syndrome

## Interventions

- **DRUG:** CTH120
- **OTHER:** CTH120 placebo hard capsules

## Key facts

- **NCT ID:** NCT07654114
- **Lead sponsor:** Connecta Therapeutics, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654114, "Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*